Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Clostridium butyricum is a butyrate-producing probiotic bacterium that has been investigated for its potential to support or treat colitis, particularly ulcerative colitis and other forms of inflammatory bowel disease (IBD). Scientific evidence for its use comes primarily from animal studies and a limited number of clinical trials in humans. In animal models of colitis, C. butyricum supplementation has demonstrated anti-inflammatory effects, preservation of gut barrier function, and modulation of gut microbiota composition. These effects are believed to be due to its production of butyrate, a short-chain fatty acid with known anti-inflammatory and mucosal-protective properties.

Human studies, though fewer, have shown promising results. For example, randomized controlled trials in patients with mild to moderate ulcerative colitis have reported improved clinical remission rates and reduced inflammatory markers when C. butyricum was used as an adjunct to standard therapy. Meta-analyses suggest a potential benefit, but emphasize the need for larger, high-quality studies.

While C. butyricum is not universally included in treatment guidelines, it is available as a probiotic supplement in some countries and is used alongside conventional therapies. The current body of evidence justifies cautious optimism, but more robust, large-scale clinical trials are needed to firmly establish its efficacy and safety for colitis. Thus, the scientific evidence supporting its use is moderate (rated 3/5).

More about Clostridium butyricum
More about Colitis

Other ingredients used for Colitis

Other health conditions supported by Clostridium butyricum

Products containing Clostridium butyricum